The largest database of trusted experimental protocols

Balloon Occlusion

Balloon Occlusion is a medical procedure where a small, inflatable balloon is used to temporarily block or occlude a blood vessel.
This technique is commonly employed in the treatment of various cardiovascular conditions, such as aneurysms, arteriovenous malformations, and certain types of bleeding.
During the procedure, the balloon is guided through the bloodstream to the target area using imaging guidance, and then inflated to restrict blood flow.
Balloon Occlusion can be a valuable tool in minimally invasive surgery, allowing for precise and controlled management of blood flow.
This procedure is typically perfromed by trained medical professionals, such as interventional radiologists or vascular surgeons, to safely and effectively address a range of vascular disorders.

Most cited protocols related to «Balloon Occlusion»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Aspiration Thrombectomy Balloon Occlusion BLOOD Cardiovascular System Catheters Contrast Media Dental Occlusion Dextran Dilatation Patients Saline Solution Vision

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Adenovirus Infections Anatomic Variation Angiocardiography Angiography Animals Arteries Artery, Coronary Balloon Occlusion Blood Vessel Cardiac Catheters Catheterization Catheterizations, Cardiac Catheters Coronary Circulation Coronary Vessels Diagnosis Heart Homo sapiens Homozygote Intubation Myocardium Nitroglycerin Obstetric Delivery Patients Pharmaceutical Preparations Safety Sheep Sus scrofa Tissues Virion
Animal investigations were carried out in accordance with the “Position of the American Heart Association on Research Animal Use,” as adopted by the AHA on November 11, 1984. The study was approved by the Ethics Committee on Animal Experimentation at the University of Kaposvar, Hungary. The study design is displayed in Fig. 1.
Domestic pigs underwent cardiac catheterization (Supplementary Methods). The r-I/R protocol consisted of three repetitive cycles of 10 min I/R via percutaneous balloon occlusion and deflation in the mid left anterior descending coronary artery (LAD) under general anesthesia. Details are described in the Supplementary Methods.
Publication 2017
Animals Artery, Coronary Balloon Occlusion Catheterizations, Cardiac Ethics Committees General Anesthesia Sus scrofa domestica
All animal studies were approved and conducted in accordance with the Animal Care Committee of Sunnybrook Research Institute. Yorkshire pigs (Caughell Farms, ON) underwent MI induction via balloon occlusion of the mid-LAD, followed 3 weeks later by thoracotomy and direct transepicardial injection of hESC-CMs or vehicle. Animals were pharmacologically immunosuppressed with cyclosporine A, methylprednisolone, and abatacept, and underwent telemetric ECG monitoring, serial cardiac MRI, and/or terminal EAM as described in Figure S1 and Supplemental Experimental Procedures.
Publication 2019
Abatacept Animal Care Committees Animals Balloon Occlusion Cyclosporine Heart Human Embryonic Stem Cells Methylprednisolone Sus scrofa Telemetry Thoracotomy
The FIRE AND ICE trial (NCT01490814) was a multicentre, randomized, blinded-outcomes, parallel-group evaluation of cryoballoon and RFC catheter ablation in patients being treated for drug-refractory and symptomatic paroxysmal AF.1 (link),2 (link) A study design manuscript and the primary endpoints have been separately published.1 (link),2 (link) In brief, each treatment centre approved the study design with their local ethics review committee(s), and patient informed consent was obtained prior to enrolment. Patients were randomized to either cryoballoon ablation using the Arctic Front™ family of catheters (Medtronic) or RFC catheter ablation using the ThermoCool® series of catheters (Biosense Webster).
During the index procedure, the (1:1) randomly selected ablation modality was used in the left atrium to electrically isolate the pulmonary veins (PVs).3–5 (link) In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a ‘single-shot’ delivery of coolant to the balloon. In the RFC procedure, PVI was achieved using a focal ‘point-by-point’ catheter approach, which delivers heat energy to the cardiac tissue. RFC lesion sets encircle the PV antra using electroanatomical mapping for guidance. In both cohorts, a PVI-only strategy was used to ablate AF, and acute index procedure success was documented in both arms with diagnostic testing. All investigators demonstrated the success of PVI by the abolition of conduction of atrial impulses into the PVs. After the index procedure, subjects were followed in this study for up to 33 months.1 (link),2 (link) In both groups, subjects were followed-up for a mean time of 1.54 ± 0.8 years.1 (link)In the publication of the primary endpoints, the data were presented as time-to-first event reported per subject, and a 90-day blanking period was predefined.1 (link) Recurrences of atrial arrhythmias and repeat ablations within the 90-day blanking period did not contribute towards the primary endpoint.1 (link) However, robust clinical data were collected (on reinterventions and rehospitalizations) in this trial both within the 90-day blanking period and after the primary endpoint event to allow for the analyses of the current presented endpoints. The data presented in this current analysis are the total clinical events that were documented in this trial from the index procedure through the study exit for each subject to provide a comprehensive summary of the disease burden to the patients and to the healthcare systems.
Publication 2016
Antral Arm, Upper Atrium, Left Balloon Occlusion Cardiac Arrhythmia Catheter Ablation Catheters Contrast Media Electric Conductivity Electricity Ex utero Intrapartum Treatment Procedures Fibrillation, Paroxysmal Atrial Fluoroscopy Heart Heart Atrium isolation Obstetric Delivery Patient Readmission Patients Pharmaceutical Preparations Radio-Opaque acrylic resin Recurrence Retention (Psychology) Tissues Veins, Pulmonary

Most recents protocols related to «Balloon Occlusion»

The study involved semi-structured interviews with two cohorts of participants: the first cohort were individuals who had been involved in pre-hospital trials (both trauma and non-trauma) in either a strategic or operational capacity (across different roles) within the UK — referred to herein as ‘Pre-hospital trial researchers’. This cohort was sampled to assess the broad challenges across pre-hospital trials. These interviews were intended to be open and without an a priori specific behaviour of interest and as such data collection was not structured around a theoretical framework. However, we did apply the Capability Opportunity Motivation-Behaviour (COM-B) framework to inform the data analysis (process outlined below). The COM-B framework was developed to understand the factors that influence behaviour, namely in relation to an individuals’ capabilities (physical/psychological), opportunities (physical/social environmental factors) and motivation (reflective/automatic) [11 (link)].
The second cohort were individuals involved in the recruitment and intervention delivery to the P-PRO study (Pre-hospital Zone 1 Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for injured patients with exsanguinating sub-diaphragmatic haemorrhage) — referred to herein as ‘P-PRO clinical investigators’. P-PRO is an observational cohort study investigating the feasibility of pre-hospital Zone 1 partial Resuscitative Endovascular Balloon Occlusion of the Aorta (P-REBOA). REBOA is a complex intervention that involves the insertion of an aortic balloon occlusion catheter into the thoracoabdominal aorta. REBOA is not routinely available within the UK in either the pre-hospital or in-hospital setting. However, this intervention is currently being evaluated in the Emergency Department setting by the UK REBOA Trial. Pre-hospital REBOA has been in use by London HEMS since 2014 targeting the distal aorta (Zone 3), for the management of severe pelvic haemorrhage [12 , 13 (link)]. Zone 1 P-REBOA describes an evolution of this technique involving balloon positioning in the thoracic aorta for patients with sub-diaphragmatic haemorrhage and severe, immediately life-threatening shock, combined with a procedural adaptation to allow some blood flow past the balloon.
In the P-PRO Study, London HEMS teams are tasked with deploying Zone 1 P-REBOA in patients in the pre-hospital setting. The balloon is positioned above the level of suspected haemorrhage and inflated to augment aortic blood pressure above the balloon whilst reducing bleeding below. Once the haemodynamics have stabilised, the balloon is partially deflated to allow some controlled distal blood flow (P-REBOA) and therefore oxygen delivery, to mitigate against the ischaemia that is otherwise created. P-PRO clinical investigators then transport patients to the nearest Major Trauma Centre, whilst managing the balloon in situ.
Interviews with the P-PRO clinical investigators were narrower in focus with specific behaviours of interest to be investigated (recruitment and intervention delivery in a future trial). As such data collection and analysis was informed by the Theoretical Domains Framework (TDF). The TDF is an established behavioural framework that integrates 33 theories of behaviour into 14 domains that inhibit or enable behaviour (knowledge, skills; social/professional role and identity; beliefs about capabilities; beliefs about consequences; optimism; reinforcement; intentions; goals; memory/attention/decision processes; environmental context and resources; social influences; emotion; behavioural regulation) [17 ]. Domains of the TDF can be mapped onto components of the COM-B framework [12 ].
Publication 2023
Acclimatization Aorta Aortic Pressure Attention Balloon Occlusion Biological Evolution Blood Circulation Cardiac Arrest Catheterization Clinical Investigators Emotions Exsanguination Hemodynamics Inpatient Ischemia Memory Motivation Obstetric Delivery Optimism Oxygen Patients Pelvis Physical Examination Reinforcement, Psychological Resuscitation Shock Thoracic Aorta Wounds and Injuries
This is a retrospective review of a consecutive series of patients with large air leaks related to SARS-CoV-2 infection. All patients were admitted to the high-volume specialist ECMO intensive care unit (ICU) at Guy’s and St Thomas’ Hospitals in London with severe respiratory failure requiring VV-ECMO. Standard lung rest settings at admission were mandatory pressure control ventilation, with driving pressure of 10 cm H2O, PEEP 10 cm H2O and a respiratory rate of 10. Patients were considered for endobronchial valve (EBV) placement if there were persistent (>10 days), large air leaks (>500 mL/min) despite conventional therapy (optimal pleural drainage, reduced mechanical ventilator pressure, lung rest, attempted recruitment of collapsed lung segments, and isolated lung ventilation and pleurodesis where indicated). Multidisciplinary discussion between teams from ICU, respiratory medicine and thoracic surgery had deemed that no other methods of management of the air leaks were feasible, including lung surgery.
EBV deployment was performed in all cases at the bedside in ICU (see Figure 1). A 2.8 size fibreoptic bronchoscope was used via the endotracheal or tracheostomy tube. Selection for the site of EBV placement was assessed using sequential balloon occlusion of lobar then segmental bronchi while observing for immediate cessation of air leak at the pleural drains. Once the source of the air leak was identified, an appropriate-sized Zephyr® endobronchial valve (4.0–5.5 mm, Pulmonx, Redwood City, CA, USA) was deployed to occlude the segment or lobe. Consent for the procedure was obtained as per hospital policy in adults who lacked capacity to consent to investigations or treatment, and risks and benefits were discussed with patients’ families. All procedures were performed by a thoracic surgeon experienced in the procedure. Maintained cessation of air leaks was subsequently confirmed with the absence of both bubbling from an under-water seal pleural drain system and measured minute volume leak on the ventilator.
Patient characteristics and clinical data were collected retrospectively from a prospectively maintained patient electronic health record (Intellispace Critical Care and Anaesthesia, Philips Healthcare, Koninklijke, Amsterdam, the Netherlands). Imaging data were collected from an electronic radiology reporting system (PACS, Sectra Medical, Linköping, Sweden). Continuous data were reported as mean and standard deviation or range, and categorical data were reported as count and percentage. Survival was measured from the date of hospital discharge. Ethical approval was sought and waived on the basis that this was a retrospective study.
Publication 2023
Adult Anesthesia Atelectasis Atrial Premature Complexes Balloon Occlusion Bronchoscopes COVID 19 Critical Care Drainage Extracorporeal Membrane Oxygenation Lung Mechanical Ventilator Patient Discharge Patients Phocidae Pleura Pleurodesis Positive End-Expiratory Pressure Pressure Pulmonary Surgical Procedures Redwood Respiratory Failure Respiratory Rate Surgeons Tertiary Bronchi Thoracic Surgical Procedures Tracheostomy X-Rays, Diagnostic
Patients diagnosed with liver cirrhosis and EGV between September 2017 and December 2021 were included in our study by retrospective review. The following were the criteria for inclusion: (1) Diagnosis of cirrhosis through histopathologic examination or a combination of clinical, laboratory, and radiologic findings; (2) Completion of a triple-phase enhanced CT scan within one week prior to endoscopy; and (3) All patients diagnosed with EGV through endoscopy. Exclusion criteria were: (1) Previous endoscopic therapy, trans jugular intrahepatic portosystemic shunt, splenectomy, splenic artery embolization, balloon occlusion, retrograde transvenous occlusion, or liver transplantation; (2) Patients with liver neoplasms; and (3) Incomplete clinical or imaging data.
As a random assignment in a 7:3 ratio, patients were divided into training and validation cohorts. Finally, there were 149 patients included in the training set, as well as 62 in the validation one. A flowchart of our study is shown in Figure 1.
Publication 2023
Balloon Occlusion Clinical Laboratory Services Dental Occlusion Embolization, Therapeutic Endoscopy Liver Cirrhosis Liver Transplantations Neoplasms, Liver Patients Splenectomy Splenic Artery Surgical Portosystemic Shunt Therapeutics X-Ray Computed Tomography
Diagnostic angiography, treatment selection, and treatment for each patient were performed by a single neurosurgeon. The decision to perform CEA or CAS was based on patient characteristics, surgical anatomy, vessel anatomy, and plaque morphology. The procedures for CEA and CAS have been previously described [22 (link)]. CAS was performed under local anesthesia using transfemoral arterial access. An embolic protection device (Emboshield NAV6 [ev3, Plymouth, Minnesota, USA]; RX Accunet [Abbott, Santa Clara, California, USA]) was carefully placed at the distal end of the stenosis. The stenosis was predilated with a balloon of appropriate size (Sterling [Boston Scientific, Marlborough, Massachusetts, USA], and the self-expanding stent (AccuLink [Abbott, Santa Clara, California, USA]). Because CAS was not performed in an emergent manner, patients received dual antiplatelets, aspirin (100 mg), and clopidogrel (75 mg daily). All patients who underwent CAS were recommended to continue dual antiplatelet therapy. CEA was performed under general anesthesia. For CEA, patients received 100 mg of aspirin daily, and those who took dual antiplatelet therapy stopped clopidogrel 5–7 days before CEA. After the Hemovac was removed, the patient continued dual antiplatelet therapy. If contralateral carotid stenosis was detected among CEA candidates, balloon occlusion tests (BOT) were performed to confirm whether patients would tolerate the procedure. An arterial shunt was used selectively for high-risk patients who could not tolerate BOT.
Publication 2023
Angiography Arteries Aspirin Balloon Occlusion Blood Vessel Carotid Stenosis Clopidogrel Dental Plaque Diagnosis Dual Anti-Platelet Therapy Embolic Protection Devices General Anesthesia Local Anesthesia Neurosurgeon Operative Surgical Procedures Patients Selection for Treatment Stenosis Stents
Baseline demographics, clinical, and outcomes data were obtained. Demographic data included gestational age, birthweight, sex, and APGAR scores at 1- and 5 min. Clinical data included fetal CDH measurements {Observed/Expected Total Fetal Lung Volume (O/E TFLV), Lung-Head Ratio (LHR) and percent liver herniation (%LH)}, severity of hernia (based on prenatal CDH measurements described by Ruano et al.) (12 (link)), side of hernia, fetal intervention such as Fetal Tracheal Balloon Occlusion (FETO), and inotropic medications used. Postnatal use of vasoactive medications was obtained for different time points: 6-, 12-, 24-, 48-HOL, on the day of CDH repair and 24- and 48 h after surgical repair. This data was extracted and screened by 2 study personnel (SHaG and CT) to ensure accuracy. We obtained echocardiographic data from the first postnatal study, following CDH surgical repair, and at 28 days of life. Echocardiographic measures included data on septal defects (presence of atrial septal defect(s) (ASD), ventricular septal defect(s) (VSD) and/or patent foramen ovale (PFO)), ASD/VSD shunt direction, tricuspid regurgitation (TR) velocity, ventricular septal position, patent ductus arteriosus (PDA) size (small, moderate and large), PDA shunt direction (left to right, right to left or bidirectional), qualitative right and left ventricular function (mild, moderate or severely depressed) and ejection fraction of LV based on American Society for Echocardiography (ASE) guidelines (13 (link)). Primary clinical outcomes were use of ECMO and mortality, and secondary clinical outcomes were duration of ECMO, length of hospital stay and postnatal echocardiographic markers.
Publication 2023
Apgar Score Atrial Septal Defects Balloon Occlusion Birth Weight Care, Prenatal Echocardiography Extracorporeal Membrane Oxygenation Foramen Ovale, Patent Gestational Age Head Heart Septal Defects Hernia Left Ventricular Function Liver Lung Lung Volumes Operative Surgical Procedures Patent Ductus Arteriosus Pharmaceutical Preparations Trachea Tricuspid Valve Insufficiency Ventricular Septal Defects Ventricular Septum

Top products related to «Balloon Occlusion»

Sourced in United States
The Maverick is a lab equipment product designed for performing various scientific and medical procedures. It serves as a versatile and reliable tool for researchers and medical professionals. The core function of the Maverick is to provide a sturdy and precise platform for conducting laboratory tasks, but a detailed description cannot be provided while maintaining an unbiased and factual approach.
Sourced in United States, Germany
The PressureWire is a medical device designed to measure intravascular pressure. It provides precise and reliable pressure measurements to support clinical decision-making.
Sourced in United States
The Maverick XL Monorail Balloon Catheter is a medical device designed for percutaneous transluminal coronary angioplasty (PTCA) procedures. It is a single-lumen balloon catheter with a monorail design, which allows for rapid exchange during the procedure.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Australia, Spain, Switzerland
SPSS Statistics version 22 is a statistical software application developed by IBM. It is designed to analyze and manipulate data, providing users with tools for data management, statistical analysis, and reporting. The software supports a wide range of data types and offers a variety of statistical procedures, enabling users to explore relationships, test hypotheses, and generate insights from their data.
Sourced in United States
The Excelsior 1018 is a laboratory centrifuge designed for general-purpose applications. It features a maximum speed of 18,000 RPM and a maximum RCF of 30,000 x g. The centrifuge can accommodate a variety of sample volumes and tube sizes. Its simple operation and reliable performance make it suitable for use in various research and clinical laboratory settings.
Sourced in United States
The MINI TREK is a compact and portable laboratory equipment designed for molecular biology applications. It provides a reliable platform for performing basic DNA/RNA amplification techniques such as PCR. The MINI TREK offers consistent temperature control and intuitive operation, making it a versatile tool for various research and clinical settings.
Sourced in United States, Germany, Sao Tome and Principe, Macao, China, Switzerland, Australia, Japan, Spain, Italy, Senegal
The TTC (Triphenyltetrazolium Chloride) is a laboratory reagent used for various analytical and diagnostic applications. It is a colorless compound that is reduced to a red formazan product in the presence of metabolically active cells or tissues. This color change is utilized to assess cell viability, detect active enzymes, and measure cellular respiration in a wide range of biological samples.
Sourced in United States
PressureWire™ X Guidewire is a pressure measurement device used in medical procedures. It is designed to assess blood pressure and flow in the cardiovascular system.
Sourced in United States
SPSS version 22.0 for Windows is a statistical software package designed to analyze data. It provides a range of statistical procedures and data management tools for researchers and data analysts.
Sourced in United States, United Kingdom, Germany
Dipeptidyl peptidase 4 inhibitor is a type of lab equipment used to measure the activity of the enzyme dipeptidyl peptidase 4 (DPP-4). DPP-4 is an enzyme that plays a role in the regulation of certain hormones, and this equipment is used to assess its function in research and clinical settings.

More about "Balloon Occlusion"

Balloon Occlusion is a minimally invasive medical procedure where a small, inflatable balloon is used to temporarily block or restrict blood flow in a targeted blood vessel.
This technique, also known as vascular occlusion or embolization, is commonly employed in the treatment of various cardiovascular conditions, such as aneurysms, arteriovenous malformations (AVMs), and certain types of bleeding.
During the procedure, the balloon is guided through the bloodstream to the target area using imaging guidance, such as fluoroscopy or CT scans.
Once in position, the balloon is inflated to restrict or occlude the blood flow, allowing for precise and controlled management of the vascular issue.
Balloon Occlusion is often utilized in minimally invasive surgeries, as it can help reduce the risk of complications and improve patient outcomes.
This procedure is typically performed by trained medical professionals, such as interventional radiologists or vascular surgeons, who have the expertise to safely and effectively address a range of vascular disorders.
Medications like Dipeptidyl peptidase 4 (DPP-4) inhibitors may be used in conjunction with Balloon Occlusion to manage certain cardiovascular conditions.
Additionally, devices such as the Maverick, PressureWire, Maverick XL Monorail Balloon Catheter, and the MINI TREK Balloon Catheter may be employed during the procedure.
The SPSS Statistics version 22 software can be utilized to analyze data related to Balloon Occlusion outcomes and efficacy.
The Excelsior 1018 and TTC (Transcatheter Therapeutics Conference) may also be relevant to this procedure and associated research.
By leveraging the insights and tools provided by platforms like PubCompare.ai, researchers can optimize their Balloon Occlusion studies, identify the best protocols and products, and enhance the reproducibility and accuracy of their findings.